In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Privia Health Group shows a significant potential upside of 96.1% versus current price, supported by a high-confidence DCF valuation around $49. Financial health reveals strong liquidity but weak profitability and high leverage, increasing risk. Monte Carlo analysis displays high volatility with a downside risk below 14%, indicating notable valuation uncertainty.